This week's Fierce Biotech is brought to you by Premier Research. Trouble viewing? Click here.
Dear E,
The cyclical nature of major depressive disorder (MDD) leaves patients vulnerable to relapse. To bring safe, effective drugs for MDD to market, regulators often demand long-term maintenance studies to truly assess the durability of the drug’s effect. But maintenance studies are resource and time intensive, requiring careful planning and disciplined execution for success.
Based on our extensive experience in psychiatry trial management, Premier experts have developed a guide to help.
Explore proven study designsUnderstand key differences between acute and maintenance studiesGet 6 keys for success in designing and operationalizing maintenance studies
Want to reach 137,000+ Fierce Biotech subscribers with your own message? Contact aalcover@questex.com or call 202-824-5074.
You are currently subscribed as newsletter@newslettercollector.com. If you no longer wish to receive communications from Fierce Biotech's trusted partners, simply click here to unsubscribe. Refer to our Privacy Policy.
Questex, LLC 685 3rd Avenue, 21st Floor New York, NY 10017
